CyFlow CD55 PE (RUO)
| 品番 | BU291965 | ||
|---|---|---|---|
| 抗体名 | Anti-Hu CD55 PE,MEM-118 | ||
| 包装単位 | 100 tests | ||
| 濃度 | - | ||
| 推奨使用量 | - | ||
| 容量 | 1 ml | ||
| 関連製品 (アイソタイプコントロール) |
Mouse IgM PE (CW330883) |
||
| 反応性|交差吸着 | Human | Non-Human Primates | レーザー | Blue, Green, Yellow |
| 抗原 | CD55, DAF | 最大蛍光波長 | 576 nm |
| クローン | MEM-118 | 最大励起波長 | 496 nm, 565 nm |
| ホスト | Mouse | 標識/Format | PE |
| アイソタイプ | IgM | 研究分野 | Immunophenotyping |
| クローナリティ | monoclonal | アプリケーション | - |
Anti-Hu CD55 PE,MEM-118
特異性
The mouse monoclonal antibody MEM-118 recognizes an epitope in SCR4 domain of CD55 antigen, a 60-70 kDa glycosylphosphatidylinositol (GPI)-anchored single chain glycoprotein. CD55 is widely expressed on hematopoietic and on many non-hematopoietic cells; it is weakly present on NK cells.
抗原情報
CD55 (DAF; decay-accelerating factor) is a GPI-anchored membrane glycoprotein that protects autologous cells from classical and alternative pathway of complement cascade. Bidirectional interactions between CD55 and CD97 are involved in T cell regulation and CD55 can still regulate complement when bound to CD97. In tumors, besides protection agains complement, CD55 promotes neoangiogenesis, tumorigenesis, invasiveness and evasion of apoptosis.
利用方法
The reagent is designed for Flow Cytometry analysis of human blood cells. Recommended usage is 10 µl reagent / 100 µl of whole blood or 10^6 cells in a suspension. The content of a vial (1 ml) is sufficient for 100 tests.
保存方法
Avoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze.
安定性情報
Do not use after expiration date stamped on vial label.
レファレンス
• Abbott RJ, Spendlove I, Roversi P, Fitzgibbon H, Knott V, Teriete P, McDonnell JM, Handford PA, Lea SM: Structural and functional characterization of a novel T cell receptor co‑regulatory protein complex, CD97‑CD55. J·Biol·Chem. 2007·Jul·27; 282(30):22023‑32. <·PMID:·17449467·>
• Angelisová P, Drbal K, Horejsí V, Cerný J: Association of CD10/neutral endopeptidase 24.11 with membrane microdomains rich in glycosylphosphatidylinositol‑anchored proteins and Lyn kinase. Blood. 1999·Feb·15; 93(4):1437‑9. <·PMID:·10075459·>
• Doussis IA, Gatter KC, Mason DY: CD68 reactivity of non‑macrophage derived tumours in cytological specimens. J·Clin·Pathol. 1993·Apr; 46(4):334‑6. <·PMID:·7684403·>
• Mikesch JH, Buerger H, Simon R, Brandt B: Decay‑accelerating factor (CD55): a versatile acting molecule in human malignancies. Biochim·Biophys·Acta. 2006·Aug; 1766(1):42‑52. <·PMID:·16784816·>
• Miwa T, Maldonado MA, Zhou L, Sun X, Luo HY, Cai D, Werth VP, Madaio MP, Eisenberg RA, Song WC: Deletion of decay‑accelerating factor (CD55 exacerbates autoimmune disease development in MRL/lpr mice. Am·J·Pathol. 2002·Sep; 161(3):1077‑86. <·PMID:·12213736·>
• Miwa T, Maldonado MA, Zhou L, Yamada K, Gilkeson GS, Eisenberg RA, Song WC: Decay‑accelerating factor ameliorates systemic autoimmune disease in MRL/lpr mice via both complement‑dependent and ‑independent mechanisms. Am·J·Pathol. 2007·Apr; 170(4):1258‑66. <·PMID:·17392165·>
• VanLandingham JW, Cekic M, Cutler S, Hoffman SW, Stein DG: Neurosteroids reduce inflammation after TBI through CD55 induction. Neurosci·Lett. 2007·Sep·25; 425(2):94‑8. <·PMID:·17826908·>